Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

Ogasawara, Annie; Kiefer, James R.; Gill, Herman; Chiang, Eugene; Sriraman, Shravan; Ferl, Gregory Z.; Ziai, James; Bohorquez, Sandra Sanabria; Guelman, Sebastian; Wang, Xiangdan; Yang, Jihong; Phan, Minh Michael; Nguyen, Van; Chung, Shan; Yu, Christine; Tinianow, Jeff; Waaijer, Stijn Jan Hein; De Crespigny, Alex; Marik, Jan; Boswell, C. Andrew; Zabka, Tanja; Staflin, Karin; Williams, Simon-Peter

doi:10.1007/s00259-022-05968-6

Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

Journal Article · 22 October 2022 · European Journal of Nuclear Medicine and Molecular Imaging

DOI:https://doi.org/10.1007/s00259-022-05968-6· OSTI ID:2423921

Ogasawara, Annie; Kiefer, James R.; Gill, Herman; Chiang, Eugene; Sriraman, Shravan; Ferl, Gregory Z.; Ziai, James; Bohorquez, Sandra Sanabria; Guelman, Sebastian; Wang, Xiangdan; Yang, Jihong; Phan, Minh Michael; Nguyen, Van; Chung, Shan; Yu, Christine; Tinianow, Jeff; Waaijer, Stijn Jan Hein; De Crespigny, Alex; Marik, Jan; Boswell, C. Andrew more »

Not provided.

Research Organization:: SLAC National Accelerator Laboratory, Menlo Park, CA (United States). Stanford Synchrotron Radiation Lightsource (SSRL)

Sponsoring Organization:: USDOE

DOE Contract Number:: AC02-76SF00515

OSTI ID:: 2423921

Journal Information:: European Journal of Nuclear Medicine and Molecular Imaging, Journal Name: European Journal of Nuclear Medicine and Molecular Imaging Journal Issue: 2 Vol. 50; ISSN 1619-7070

Publisher:: Springer Nature

Country of Publication:: United States

Language:: English

References (54)

Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector Function in the Absence of TCR Engagement and Improve Peptide–MHCI Tetramer Staining Clement, Mathew; Ladell, Kristin; Ekeruche-Makinde, Julia The Journal of Immunology, Vol. 187, Issue 2 https://doi.org/10.4049/jimmunol.1003941	journal	July 2011
Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics Rafidi, Hanine; Estevez, Alberto; Ferl, Gregory Z. Molecular Cancer Therapeutics, Vol. 20, Issue 10 https://doi.org/10.1158/1535-7163.MCT-21-0116	journal	July 2021
Pharmacokinetics and Biodistribution of a [⁸⁹Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients O’Donoghue, Joseph A.; Danila, Daniel C.; Pandit-Taskar, Neeta Molecular Pharmaceutics, Vol. 16, Issue 7 https://doi.org/10.1021/acs.molpharmaceut.9b00326	journal	May 2019
The Production, Quality Control, and Characterization of ZED8, a CD8-Specific 89Zr-Labeled Immuno-PET Clinical Imaging Agent Gill, Herman; Seipert, Richard; Carroll, Vincent M. The AAPS Journal, Vol. 22, Issue 2 https://doi.org/10.1208/s12248-019-0392-0	journal	January 2020
In vivo biodistribution and accumulation of 89Zr in mice Abou, Diane S.; Ku, Thomas; Smith-Jones, Peter M. Nuclear Medicine and Biology, Vol. 38, Issue 5 https://doi.org/10.1016/j.nucmedbio.2010.12.011	journal	July 2011
Ultrafast Preconditioned Conjugate Gradient OSEM algorithm for fully 3D PET reconstruction Hong, I. K.; Burbar, Z.; Michel, C. IEEE Nuclear Science Symposuim & Medical Imaging Conference https://doi.org/10.1109/NSSMIC.2010.5874221	conference	October 2010
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer Bensch, Frederike; van der Veen, Elly L.; Lub-de Hooge, Marjolijn N. Nature Medicine, Vol. 24, Issue 12 https://doi.org/10.1038/s41591-018-0255-8	journal	November 2018
A review of background findings in cynomolgus monkeys (Macaca fascicularis) from three different geographical origins Drevon-Gaillot, Elodie; Perron-Lepage, Marie-France; Clément, Christian Experimental and Toxicologic Pathology, Vol. 58, Issue 2-3 https://doi.org/10.1016/j.etp.2006.07.003	journal	November 2006
PD-1 blockade induces responses by inhibiting adaptive immune resistance Tumeh, Paul C.; Harview, Christina L.; Yearley, Jennifer H. Nature, Vol. 515, Issue 7528 https://doi.org/10.1038/nature13954	journal	November 2014
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer Seo, A. N.; Lee, H. J.; Kim, E. J. British Journal of Cancer, Vol. 109, Issue 10 https://doi.org/10.1038/bjc.2013.634	journal	October 2013
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody Carrasquillo, Jorge A.; Fine, Bernard M.; Pandit-Taskar, Neeta Journal of Nuclear Medicine, Vol. 60, Issue 11 https://doi.org/10.2967/jnumed.118.222844	journal	May 2019
The calm after the cytokine storm: lessons from the TGN1412 trial St. Clair, E. William Journal of Clinical Investigation, Vol. 118, Issue 4 https://doi.org/10.1172/JCI35382	journal	April 2008
Factors determining antibody distribution in tumors Thurber, G.; Schmidt, M.; Wittrup, K. Trends in Pharmacological Sciences https://doi.org/10.1016/j.tips.2007.11.004	journal	January 2008
Tumor infiltrating lymphocytes in ovarian cancer Santoiemma, Phillip P.; Powell, Daniel J. Cancer Biology & Therapy, Vol. 16, Issue 6 https://doi.org/10.1080/15384047.2015.1040960	journal	April 2015
Role of MetMAb (OA-5D5) in c-MET active lung malignancies Surati, Mosmi; Patel, Premal; Peterson, Amy Expert Opinion on Biological Therapy, Vol. 11, Issue 12 https://doi.org/10.1517/14712598.2011.626762	journal	October 2011
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer Laforest, Richard; Lapi, Suzanne E.; Oyama, Reiko Molecular Imaging and Biology, Vol. 18, Issue 6 https://doi.org/10.1007/s11307-016-0951-z	journal	May 2016
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody Farwell, Michael D.; Gamache, Raymond F.; Babazada, Hasan Journal of Nuclear Medicine https://doi.org/10.2967/jnumed.121.262485	journal	August 2021
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Salgia, Ravi; Patel, Premal; Bothos, John Clinical Cancer Research, Vol. 20, Issue 6 https://doi.org/10.1158/1078-0432.CCR-13-2070	journal	March 2014
CD8 ⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review Farhood, Bagher; Najafi, Masoud; Mortezaee, Keywan Journal of Cellular Physiology, Vol. 234, Issue 6 https://doi.org/10.1002/jcp.27782	journal	November 2018
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET Vugts, Danielle J.; Klaver, Chris; Sewing, Claudia European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, Issue 2 https://doi.org/10.1007/s00259-016-3499-x	journal	August 2016
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade Rashidian, Mohammad; LaFleur, Martin W.; Verschoor, Vincent L. Proceedings of the National Academy of Sciences, Vol. 116, Issue 34 https://doi.org/10.1073/pnas.1905005116	journal	August 2019
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial Gebhart, G.; Lamberts, L. E.; Wimana, Z. Annals of Oncology, Vol. 27, Issue 4 https://doi.org/10.1093/annonc/mdv577	journal	November 2015
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies Spiess, Christoph; Merchant, Mark; Huang, Arthur Nature Biotechnology, Vol. 31, Issue 8 https://doi.org/10.1038/nbt.2621	journal	July 2013
Resolution and noise properties of MAP reconstruction for fully 3-D PET No authors listed IEEE Transactions on Medical Imaging, Vol. 19, Issue 5 https://doi.org/10.1109/42.870259	journal	May 2000
Ultrasonography of the normal kidney in the cynomolgus monkey (Macaca fascicularis): morphologic and Doppler findings Gaschen, Lorrie; Menninger, Klaus; Schuurman, Henk‐Jan Journal of Medical Primatology, Vol. 29, Issue 2 https://doi.org/10.1034/j.1600-0684.2000.290205.x	journal	April 2000
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting Pandit-Taskar, Neeta; Postow, Michael A.; Hellmann, Matthew D. Journal of Nuclear Medicine, Vol. 61, Issue 4 https://doi.org/10.2967/jnumed.119.229781	journal	October 2019
Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones? Roitman, Pablo D.; Farfalli, Germán L.; Ayerza, Miguel A. Clinical Orthopaedics & Related Research, Vol. 475, Issue 3 https://doi.org/10.1007/s11999-016-4738-y	journal	March 2017
Optimization of ⁸⁹Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom Christian, Paul E.; Williams, Simon-Peter; Burrell, Lance Journal of Nuclear Medicine Technology, Vol. 48, Issue 1 https://doi.org/10.2967/jnmt.119.230474	journal	October 2019
Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification Brey, Eric M.; Lalani, Zahid; Johnston, Carol Journal of Histochemistry & Cytochemistry, Vol. 51, Issue 5 https://doi.org/10.1177/002215540305100503	journal	May 2003
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? Deng, Rong; Iyer, Suhasini; Theil, Frank-Peter mAbs, Vol. 3, Issue 1 https://doi.org/10.4161/mabs.3.1.13799	journal	January 2011
89Zr-Bevacizumab PET Imaging in Primary Breast Cancer Gaykema, S. B. M.; Brouwers, A. H.; Lub-de Hooge, M. N. Journal of Nuclear Medicine, Vol. 54, Issue 7 https://doi.org/10.2967/jnumed.112.117218	journal	May 2013
PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of ⁸⁹Zr-Cetuximab Makris, Nikolaos E.; Boellaard, Ronald; van Lingen, Arthur Journal of Nuclear Medicine, Vol. 56, Issue 2 https://doi.org/10.2967/jnumed.114.147819	journal	January 2015
Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology Pisaneschi, Federica; Viola, Nerissa T. Molecular Imaging and Biology, Vol. 24, Issue 1 https://doi.org/10.1007/s11307-021-01645-6	journal	September 2021
Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities Wang, Xiangdan; Phan, Minh Michael; Li, Ji Antibodies, Vol. 9, Issue 2 https://doi.org/10.3390/antib9020007	journal	March 2020
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer Ledys, Fanny; Klopfenstein, Quentin; Truntzer, Caroline Journal for ImmunoTherapy of Cancer, Vol. 6, Issue 1 https://doi.org/10.1186/s40425-018-0438-3	journal	November 2018
Structural Basis of the CD8αβ/MHC Class I Interaction: Focused Recognition Orients CD8β to a T Cell Proximal Position Wang, Rui; Natarajan, Kannan; Margulies, David H. The Journal of Immunology, Vol. 183, Issue 4 https://doi.org/10.4049/jimmunol.0901276	journal	July 2009
An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes Patra, Malay; Bauman, Andreas; Mari, Cristina Chem. Commun., Vol. 50, Issue 78 https://doi.org/10.1039/c4cc05558f	journal	January 2014
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error Shipitsin, M.; Small, C.; Choudhury, S. British Journal of Cancer, Vol. 111, Issue 6 https://doi.org/10.1038/bjc.2014.396	journal	July 2014
Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development Xiang, Hong; Bender, Brendan C.; Reyes, Arthur E. Clinical Cancer Research, Vol. 19, Issue 18 https://doi.org/10.1158/1078-0432.CCR-13-0260	journal	July 2013
Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor de Ruijter, Laura Kist; van de Donk, Pim P.; Hooiveld-Noeken, Jahlisa S. Cancer Research, Vol. 81, Issue 13_Supplement https://doi.org/10.1158/1538-7445.AM2021-LB037	journal	July 2021
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor Cell, Vol. 170, Issue 6 https://doi.org/10.1016/j.cell.2017.08.027	journal	September 2017
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart New England Journal of Medicine, Vol. 366, Issue 10 https://doi.org/10.1056/NEJMoa1113205	journal	March 2012
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions Schlothauer, Tilman; Herter, Sylvia; Koller, Claudia Ferrara Protein Engineering Design and Selection, Vol. 29, Issue 10 https://doi.org/10.1093/protein/gzw040	journal	August 2016
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner* Badawi, Ramsey D.; Shi, Hongcheng; Hu, Pengcheng Journal of Nuclear Medicine, Vol. 60, Issue 3 https://doi.org/10.2967/jnumed.119.226498	journal	February 2019
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Merchant, M.; Ma, X.; Maun, H. R. Proceedings of the National Academy of Sciences, Vol. 110, Issue 32 https://doi.org/10.1073/pnas.1302725110	journal	July 2013
Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Yamashita, Kohei; Iwatsuki, Masaaki; Harada, Kazuto British Journal of Cancer, Vol. 121, Issue 3 https://doi.org/10.1038/s41416-019-0515-5	journal	July 2019
Total-Body PET and Highly Stable Chelators Together Enable Meaningful ⁸⁹ Zr-Antibody PET Studies up to 30 Days After Injection Berg, Eric; Gill, Herman; Marik, Jan Journal of Nuclear Medicine, Vol. 61, Issue 3 https://doi.org/10.2967/jnumed.119.230961	journal	September 2019
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment Edwards, Jarem; Wilmott, James S.; Madore, Jason Clinical Cancer Research, Vol. 24, Issue 13 https://doi.org/10.1158/1078-0432.CCR-17-2257	journal	July 2018
Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab Jagoda, Elaine M.; Lang, Lixin; Bhadrasetty, Veerendra Journal of Nuclear Medicine, Vol. 53, Issue 10 https://doi.org/10.2967/jnumed.111.102293	journal	August 2012
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications van Dongen, G. A. M. S.; Visser, G. W. M.; Lub-de Hooge, M. N. The Oncologist, Vol. 12, Issue 12 https://doi.org/10.1634/theoncologist.12-12-1379	journal	December 2007
‘Knobs-into-holes’ engineering of antibody C _H 3 domains for heavy chain heterodimerization Ridgway, John B. B.; Presta, Leonard G.; Carter, Paul "Protein Engineering, Design and Selection", Vol. 9, Issue 7 https://doi.org/10.1093/protein/9.7.617	journal	January 1996
Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET Chomet, Marion; Schreurs, Maxime; Bolijn, Maria J. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Issue 3 https://doi.org/10.1007/s00259-020-05002-7	journal	September 2020
Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging Sriraman, Shravan Kumar; Davies, Christopher W.; Gill, Herman European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Issue 3 https://doi.org/10.1007/s00259-022-05998-0	journal	November 2022
Immune infiltration in human tumors: a prognostic factor that should not be ignored Pagès, F.; Galon, J.; Dieu-Nosjean, M-C Oncogene, Vol. 29, Issue 8 https://doi.org/10.1038/onc.2009.416	journal	November 2009

Similar Records

Importance of Extracranial Disease Status and Tumor Subtype for Patients Undergoing Radiosurgery for Breast Cancer Brain Metastases

Journal Article · 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22058942

Immunotherapy of murine bladder cancer by irradiated tumor vaccine

Journal Article · 1990 · Journal of Urology; (USA) · OSTI ID:6037382

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer

Journal Article · 2018 · Breast Cancer Research and Treatment · OSTI ID:1537724

Related Subjects

Radiology
Nuclear Medicine & Medical Imaging

Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

Citation Formats

References (54)

Similar Records

Related Subjects